Beyond GI AEs, semaglutide was found to associate with a higher incidence of gallbladder-related disorders, primarily cholelithiasis [13, 40, 42, 44,45,46], and acute pancreatitis [13, 39, 42, 44] compared with placebo
Janumet (sitagliptin/metformin) for type 2 diabetes Janumet is an oral prescription medication designed to treat type 2 diabetes
This can lead to: Increased hunger More frequent cravings Larger portion sizes Difficulty maintaining calorie balance Additionally, the body naturally tries to protect against weight loss
The same reporting described how many peptide products then appeared more often as research-only materials, while human clinical evidence for many compounds remained limited
But the trajectory seems clear: WADA is analysing the matter with requisite seriousness